(8)
(16)
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF0208, RRID:AB_2833395.
展开/折叠
ACTFS; Double minute 2 protein; E3 ubiquitin-protein ligase Mdm2; Hdm 2; Hdm2; HDMX; MDM 2; MDM2; MDM2 oncogene E3 ubiquitin protein ligase; Mdm2 p53 E3 ubiquitin protein ligase homolog; Mdm2 transformed 3T3 cell double minute 2 p53 binding protein (mouse) binding protein 104kDa; MDM2_HUMAN; MDM2BP; Mouse Double Minute 2; MTBP; Murine Double Minute Chromosome 2; Oncoprotein Mdm2; p53 Binding Protein Mdm2; p53-binding protein Mdm2; Ubiquitin protein ligase E3 Mdm2; Ubiquitin protein ligase E3 Mdm2;
抗原和靶标
Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B, isoform Mdm2-C, isoform Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and isoform Mdm2-G are observed in a range of cancers but absent in normal tissues.
- Q00987 MDM2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP
种属预测
score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - Q00987 作为底物
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| Ubiquitination | Uniprot | ||
| T4 | Phosphorylation | Uniprot | |
| S17 | Phosphorylation | Uniprot | |
| K36 | Ubiquitination | Uniprot | |
| K39 | Ubiquitination | Uniprot | |
| K45 | Ubiquitination | Uniprot | |
| Y60 | Phosphorylation | Uniprot | |
| K70 | Ubiquitination | Uniprot | |
| C77 | S-Nitrosylation | Uniprot | |
| K94 | Ubiquitination | Uniprot | |
| K98 | Ubiquitination | Uniprot | |
| S118 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S121 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| K146 | Ubiquitination | Uniprot | |
| S148 | Phosphorylation | Uniprot | |
| S157 | Phosphorylation | P49137 (MAPKAPK2) | Uniprot |
| T158 | Phosphorylation | Q9NQU5 (PAK6) | Uniprot |
| S160 | Phosphorylation | Uniprot | |
| S166 | Phosphorylation | P48730 (CSNK1D) , P11309 (PIM1) , O00141 (SGK1) , P31749 (AKT1) , P49137 (MAPKAPK2) , P31751 (AKT2) , Q9P1W9 (PIM2) , O43293 (DAPK3) | Uniprot |
| T168 | Phosphorylation | Uniprot | |
| S172 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S176 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| K182 | Acetylation | Uniprot | |
| K185 | Acetylation | Uniprot | |
| S186 | Phosphorylation | Q9NQU5 (PAK6) , Q9P1W9 (PIM2) , P11309 (PIM1) , O43293 (DAPK3) , P31749 (AKT1) , P31751 (AKT2) | Uniprot |
| S188 | Phosphorylation | P31749 (AKT1) | Uniprot |
| S190 | Phosphorylation | Uniprot | |
| S192 | Phosphorylation | Uniprot | |
| S196 | Phosphorylation | Uniprot | |
| T216 | Phosphorylation | Uniprot | |
| T218 | Phosphorylation | Uniprot | |
| S220 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S229 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S240 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S242 | Phosphorylation | Uniprot | |
| S246 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S253 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S256 | Phosphorylation | Uniprot | |
| S260 | Phosphorylation | P68400 (CSNK2A1) , P48730 (CSNK1D) , P53350 (PLK1) | Uniprot |
| S262 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S269 | Phosphorylation | P48730 (CSNK1D) , P68400 (CSNK2A1) | Uniprot |
| Y276 | Phosphorylation | P00519 (ABL1) | Uniprot |
| T279 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| Y281 | Phosphorylation | P12931 (SRC) | Uniprot |
| S286 | Phosphorylation | Uniprot | |
| T288 | Phosphorylation | Uniprot | |
| S290 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| Y302 | Phosphorylation | P12931 (SRC) | Uniprot |
| T306 | Phosphorylation | Uniprot | |
| S307 | Phosphorylation | Uniprot | |
| K334 | Ubiquitination | Uniprot | |
| K336 | Ubiquitination | Uniprot | |
| K338 | Ubiquitination | Uniprot | |
| S342 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| K344 | Ubiquitination | Uniprot | |
| K346 | Ubiquitination | Uniprot | |
| S350 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| T351 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| K363 | Ubiquitination | Uniprot | |
| K364 | Ubiquitination | Uniprot | |
| T365 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S373 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S386 | Phosphorylation | Q13315 (ATM) , P48730 (CSNK1D) | Uniprot |
| S388 | Phosphorylation | Uniprot | |
| Y394 | Phosphorylation | A0A173G4P4 (Abl fusion) , P00519 (ABL1) | Uniprot |
| S395 | Phosphorylation | Q13315 (ATM) | Uniprot |
| Y405 | Phosphorylation | P00519 (ABL1) | Uniprot |
| S406 | Phosphorylation | Uniprot | |
| S407 | Phosphorylation | Q13535 (ATR) | Uniprot |
| T419 | Phosphorylation | P48730 (CSNK1D) | Uniprot |
| S425 | Phosphorylation | Uniprot | |
| S429 | Phosphorylation | Q13315 (ATM) | Uniprot |
| K446 | Sumoylation | Uniprot | |
| K446 | Ubiquitination | Uniprot | |
| K454 | Ubiquitination | Uniprot | |
| K466 | Ubiquitination | Uniprot | |
| K467 | Ubiquitination | Uniprot | |
| K473 | Ubiquitination | Uniprot |
研究背景
E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation. Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells (By similarity). Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis (By similarity).
Phosphorylation on Ser-166 by SGK1 activates ubiquitination of p53/TP53. Phosphorylated at multiple sites near the RING domain by ATM upon DNA damage; this prevents oligomerization and E3 ligase processivity and impedes constitutive p53/TP53 degradation.
Autoubiquitination leads to proteasomal degradation; resulting in p53/TP53 activation it may be regulated by SFN. Also ubiquitinated by TRIM13. Deubiquitinated by USP2 leads to its accumulation and increases deubiquitination and degradation of p53/TP53. Deubiquitinated by USP7 leading to its stabilization.
Nucleus>Nucleoplasm. Cytoplasm. Nucleus>Nucleolus.
Note: Expressed predominantly in the nucleoplasm. Interaction with ARF(P14) results in the localization of both proteins to the nucleolus. The nucleolar localization signals in both ARF(P14) and MDM2 may be necessary to allow efficient nucleolar localization of both proteins. Colocalizes with RASSF1 isoform A in the nucleus.
Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B, isoform Mdm2-C, isoform Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and isoform Mdm2-G are observed in a range of cancers but absent in normal tissues.
Interacts with p53/TP53, TP73/p73, RBL5 and RP11. Binds specifically to RNA. Can interact with RB1, E1A-associated protein EP300 and the E2F1 transcription factor. Forms a ternary complex with p53/TP53 and WWOX. Interacts with CDKN2AIP, RFWD3, USP7, PYHIN1, and RBBP6. Interacts with ARRB1 and ARRB2. Interacts with PSMA3. Found in a trimeric complex with MDM2, MDM4 and USP2. Interacts with USP2 (via N-terminus and C-terminus). Interacts with MDM4. Part of a complex with MDM2, DAXX, RASSF1 and USP7. Part of a complex with DAXX, MDM2 and USP7. Interacts directly with DAXX and USP7. Interacts (via C-terminus) with RASSF1 isoform A (via N-terminus); the interaction is independent of TP53. Interacts with APEX1; leading to its ubiquitination and degradation. Interacts with RYBP; this inhibits ubiquitination of TP53. Identified in a complex with RYBP and p53/TP53. Also component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in regulating p53/TP53 stabilization and activity. Binds directly both p53/TP53 and TRIM28. Component of the TRIM28/KAP1-ERBB4-MDM2 complex involved in connecting growth factor responses with DNA damage. Interacts directly with both TRIM28 and ERBB4 in the complex. Interacts with DYRK2. Interacts with IGF1R. Interacts with TRIM13; the interaction ubiquitinates MDM2 leading to its proteasomal degradation. Interacts with SNAI1; this interaction promotes SNAI1 ubiquitination. Interacts with NOTCH1 (via intracellular domain). Interacts with FHIT. Interacts with RFFL and RNF34; the interaction stabilizes MDM2. Interacts with CDK5RAP3 and CDKN2A/ARF; form a ternary complex involved in regulation of p53/TP53. Interacts with MTA1. Interacts with AARB2. Interacts with MTBP. Interacts with PML. Interacts with TBRG1. Interacts with the 5S RNP which is composed of the 5S RNA, RPL5 and RPL11; the interaction is direct, occurs in the nucleoplasm and negatively regulates MDM2-mediated TP53 ubiquitination and degradation. Interacts with ADGRB1; the interaction results in inhibition of MDM2-mediated ubiquitination and degradation of DLG4/PSD95, promoting DLG4 stability and regulating synaptic plasticity (By similarity). Interacts with RPL23A; this interaction may promote p53/TP53 polyubiquitination.
(Microbial infection) Interacts with herpes virus 8 protein v-IRF4.
(Microbial infection) Interacts with and ubiquitinates HIV-1 Tat.
Region I is sufficient for binding p53 and inhibiting its G1 arrest and apoptosis functions. It also binds p73 and E2F1. Region II contains most of a central acidic region required for interaction with ribosomal protein L5 and a putative C4-type zinc finger. The RING finger domain which coordinates two molecules of zinc interacts specifically with RNA whether or not zinc is present and mediates the heterooligomerization with MDM4. It is also essential for its ubiquitin ligase E3 activity toward p53 and itself.
Belongs to the MDM2/MDM4 family.
研究领域
· Cellular Processes > Cell growth and death > Cell cycle. (View pathway)
· Cellular Processes > Cell growth and death > p53 signaling pathway. (View pathway)
· Cellular Processes > Transport and catabolism > Endocytosis. (View pathway)
· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)
· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)
· Genetic Information Processing > Folding, sorting and degradation > Ubiquitin mediated proteolysis. (View pathway)
· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.
· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.
· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.
· Human Diseases > Cancers: Overview > Viral carcinogenesis.
· Human Diseases > Cancers: Overview > Proteoglycans in cancer.
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.
· Human Diseases > Cancers: Specific types > Glioma. (View pathway)
· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)
· Human Diseases > Cancers: Specific types > Bladder cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)
· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)
文献引用
Application: WB Species: Human Sample: HL-7702 cells
Application: IF/ICC Species: Human Sample: HL-7702 cells
Application: WB Species: Human Sample: MCF-7 cells
Application: WB Species: Mouse Sample:
Application: WB Species: Rat Sample: cardiac tissue
Application: WB Species: Rat Sample: H9c2 cells
Application: WB Species: human Sample: HEL cells.
Application: WB Species: human Sample: HaCaT cells
限制条款
产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.